

## EDITORIAL COMMENT

# The Hippo in the Clinic

## An Ancient Signaling Pathway That Regulates Growth and Development Confronts a Modern Pandemic of Obesity, Diabetes, and Heart Failure\*

Sheldon H. Gottlieb, MD



The relentless expansion of the worldwide waist (1,2) has led to accelerating rates of glycemic, liver, and heart failure, some cancers, and degenerative joint disease in persons around the globe (3). “Heart failure,” a clinical syndrome that until the arrival of the obesity pandemic was typically categorized by cardiac enlargement with sodium and water overload, has become, in the modern era of ubiquitous obesity, a concatenation of multiple chronic conditions (4) that clinically present as a dysfunction of diastolic filling (5). The physiology of heart failure with preserved ejection fraction is strongly related to central obesity and diabetes (6); the clinical syndrome of heart failure with preserved ejection fraction (colloquially HEFPEF) can be defined by a point system (7). These operational definitions just hint at the clinical reality: that the phenotype of diastolic heart failure lies at the intersection of obesity (reflecting poor nutrition and associated high dietary sodium content), with type 2 diabetes, hypertension, social stress, and aging (8). The modern heart failure patients’ internal milieu is unprecedented in evolutionary history.

It is curious that none of the recent reviews of diastolic dysfunction heart failure and its obesity phenotypes discuss an ancient signaling pathway that

regulates growth and development central to every aspect of cardiovascular physiology, from apoptosis to Z-discs: the Hippo signaling pathway (Hippo) (9). The Hpo gene, which was discovered in the fruit fly, is homologous with the mammalian kinases Mst1 and Mst2 (10). Hippo regulates downstream levels of Yes Associated Protein (YAP), which interacts with transcriptional regulator TEAD1. Hippo is a highly conserved premetazoan kinase cascade; it possibly developed in response to selective pressure to facilitate communication between unicellular organisms (11). The nearly simultaneous discovery by 5 laboratories of the gene Hpo (its evocative name Hippo inspired by the overgrowth of the *Drosophila* eye imaginal disc with cellular disarray resembling the head of a hippopotamus) is reviewed (12,13). Hippo has been shown to regulate cell-to-cell contact, cell death and repair after myocardial infarction, dedifferentiation of cardiomyocytes to fibrocytes, and differentiation of stem cells to cardiomyocytes. It plays a regulatory role in the interaction of glucose and the heart (14).

SEE PAGE 611

In this issue of *JACC: Basic to Translational Science*, Ikeda et al. (15) present a proof of concept experiment of Hippo and its downstream effector YAP in a male mouse model of “metabolic syndrome” as defined by the intersection of obesity, type 2 diabetes, hypertension, and inflammation in their high fat diet (HFD), pressure overload (PO) via transverse aortic constriction (TAC) model. They have shown, in a series of publications (16,17), how YAP and associated transcriptional effector TEAD are modified. They investigated the interaction of these interventions with levels of YAP and associated pathways in their model, and after blockade of the pathways with verteporfin, which is a small-molecule specific inhibitor

\*Editorials published in *JACC: Basic to Translational Science* reflect the views of the authors and do not necessarily represent the views of *JACC: Basic to Translational Science* or the American College of Cardiology.

From the Division of Cardiology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, Baltimore, Maryland. The author has reported that he has no relationships relevant to the contents of this paper to disclose.

The author attests they are in compliance with human studies committees and animal welfare regulations of the authors’ institutions and Food and Drug Administration guidelines, including patient consent where appropriate. For more information, visit the *JACC: Basic to Translational Science* [author instructions page](#).

of the YAP pathway (18). They also obtained interesting proof of concept data from myocardial biopsy specimens from human subjects with and without type 2 diabetes; they found that the concentration of YAP in the biopsy specimens was proportional to the patient's hemoglobin A<sub>1C</sub> level. Based on these findings, they speculate that inhibitors of YAP or transcriptional effector TEAD1 may be effective in treating heart failure, as frequently seen in patients with type 2 diabetes and hypertension.

Of note in the Ikeda et al. (15) study is the possible interaction of glycemic dysregulation with PO in their HFD mouse model, where YAP overexpression, instead of protecting cardiomyocytes, may induce dedifferentiation and apoptosis. A model of metabolic syndrome in swine fed a high-fat diet and with PO with TAC has been published; an editorial expresses caution and support for animal models of metabolic syndrome (19).

Because of its role in regulating tissue growth, and its effect on tumorigenesis, there is interest in finding pharmacologic blockers and enhancers of Hippo; hundreds of compounds are currently being tested to block the central kinase of Hippo (20). Triastuti et al. (21) have used a blocker of the central Hippo kinase,

to demonstrate that increase of the YAP-complex protects the mouse heart against PO. There are concerns regarding chronic treatment with small molecule kinase inhibitors because of the association of Hippo with tumorigenesis (20).

About a third of patients with aortic stenosis have type 2 diabetes (22). How the natural history of aortic stenosis could be modified by the interactions of type 2 diabetes with the central pressure and often volume overload of aortic stenosis, by manipulation of Hippo, is unstudied and speculative.

In summary, Hippo interacts with all levels of cardiovascular physiology. The mouse model used by Ikeda et al. (15) and others has provided important insights regarding Hippo and the heart, which may lead not only to treatment for diabetic pressure overload cardiomyopathy, but also for myocardial regeneration and prevention of heart failure after myocardial infarction (23). Hippo: it really is big.

---

**ADDRESS FOR CORRESPONDENCE:** Dr. Sheldon H. Gottlieb, Division of Cardiology, Johns Hopkins University School of Medicine, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, Maryland 21224. E-mail: sgottli@jhmi.edu.

---

## REFERENCES

- Taylor C. World wide waist. *Time* 2001;157:82.
- Centers for Disease Control and Prevention. National Center for Chronic Disease Prevention and Health Promotion, Division of Nutrition, Physical Activity, and Obesity. Data, trend and maps [online]. Available at: <https://www.cdc.gov/nccdphp/dnpao/data-trends-maps/index.html>. Accessed August 10, 2019.
- GBD 2015 Obesity Collaborators. Health effects of overweight and obesity in 195 countries over 25 years. *N Engl J Med* 2017;377:13-27.
- Triposkiadis F, Giamouzis G, Parissis J, et al. Reframing the association and significance of comorbidities in heart failure. *Eur J Heart Fail* 2016;18:744-58.
- Little WC. Heart failure with a normal left ventricular ejection fraction: diastolic heart failure. *Trans Am Clin Clim Assoc* 2008;119:93-101.
- Selvaraj S, Martinez EE, Aguilar FG, et al. Association of central adiposity with adverse cardiac mechanics: findings from the Hypertension Genetic Epidemiology Network Study. *Circ Cardiovasc Imaging* 2016;9:e004396.
- Reddy YNV, Carter RE, Obokata M, Redfield MM, Borlaug BA. A simple, evidence-based approach to help guide diagnosis of heart failure with preserved ejection fraction. *Circulation* 2018;138:861-70.
- Tromp J, Shen L, Jhund PS, et al. Age-related characteristics and outcomes of patients with heart failure with preserved ejection fraction. *J Am Coll Cardiol* 2019;74:601-12.
- Gabriel BM, Hamilton DL, Tremblay AM, Wackerhage H. The Hippo signal transduction network for exercise physiologists. *J Appl Physiol* 2016;120:1105-17.
- Ardestani A, Lupse B, Maedler K. Hippo signaling: key emerging pathway in cellular and whole-body metabolism. *Trends Endocrinol Metab* 2018;29:492-509.
- Sebé-Pedrós A, Zheng Y, Ruiz-Trillo I, Pan D. Premetazoan origin of the hippo signaling pathway. *Cell Rep* 2012;1:13-20.
- Gokhale R, Pflieger CM. The power of *Drosophila* genetics: the discovery of the Hippo Pathway. *Methods Mol Biol* 2019;1893:3-26.
- Badouel C, McNeill H. SnapShot: the Hippo signaling pathway. *Cell* 2011;145:484.
- Koo JH, Guan K-L. Interplay between YAP/TAZ and metabolism. *Cell Metab Review* 2018;28:196-206.
- Ikeda S, Mukai R, Mizushima W, et al. Yes-associated protein (YAP) facilitates pressure-overload-induced dysfunction in the diabetic heart. *J Am Coll Cardio Basic Trans Science* 2019;4:611-22.
- Byun J, Del Re DP, Zhai P, et al. Yes-associated protein (YAP) mediates adaptive cardiac hypertrophy in response to pressure overload. *J Biol Chem* 2019;294:3603-17.
- Ikeda S, Mizushima W, Sciarretta S, et al. Hippo deficiency leads to cardiac dysfunction accompanied by cardiomyocyte dedifferentiation during pressure overload. *Circ Res* 2019;124:292-305.
- Prins KW, Thenappan T, Weir EK, Kalra R, Pritzker M, Archer SL. Repurposing medications for treatment of pulmonary arterial hypertension: what's old is new again. *J Am Heart Assoc* 2019;8:e011343.
- Sharp TE 3rd, Lefer DJ, Houser SR. Cardiomitochondrial heart failure and HFpEF: still chasing unicorns. *J Am Coll Cardiol Basic Trans Science* 2019;4:422-4.
- Crawford JJ, Bronner SM, Zbieg JR. Hippo pathway inhibition by blocking the YAP/TAZ-TEAD interface: a patent review. *Expert Opin Ther Patents* 2018;28:867-73.
- Triastuti E, Nugroho AB, Zi M, et al. Pharmacological inhibition of Hippo pathway using XMU-MP-1 protects the heart against adverse effects during pressure overload. *Br J Pharmacol* 2019 Jul 22 [E-pub ahead of print].
- Banovic M, Athithan L, McCann GP. Aortic stenosis and diabetes mellitus: an ominous combination. *Diab Vasc Dis Res* 2019;16:310-23.
- Heallen TR, Kadow ZA, Kim JH, Wang J, Martin JF. Stimulating cardiogenesis as a treatment for heart failure. *Circ Res* 2019;124:1647-57.

---

**KEY WORDS** diabetes, diastolic heart failure, Hippo pathway, mouse model metabolic syndrome, Yes-associated protein (YAP)